[Discontinued]
Kit for the determination of the CTG triplet repeats number of the DMPK gene by fluorescent fragment analysisMyotonic dystrophy type 1 or Steinert’s disease is currently the most common form of muscular dystrophy in adults. Inheritance of this multisystem disease is autosomal dominant, and phenotypic expression is highly variable due to an unstable expansion CTG trinucleotide repeats dystrophia myotonica protein kinase gene (DMPK, MIM*605377).
There is a correlation between the number of CTG repeats and the age of appearance and severity of symptoms:
Adellgene® Myotonic Dystrophy Screening is a semi-automated in vitro diagnostic kit designed for use in clinical laboratories which quantitatively determines the number of repetitions of CTG (cytosine-thymine-guanine) of 3´UTR region of the DMPK gene located in chromosome 19 resulting in Myotonic Dystrophy Type 1 (DM1) disease. It aims to aid diagnosis associated with clinical findings in DM1 that span from mild to severe symptoms.
The use of this kit is the determination of healthy alleles who have between 5 to 49, patients with mild phenotype (50-100 repeats) and classic (100-1000) until 150 repeats. In the cases of homozygous individuals which allele detected is less than 150 repeats or no allele is detected a subsequent study with Adellgene® Myotonic Dystrophy Confirmatory kit must be done to establish the definition of alleles of more than 150 repeats.
The technology is based on the polymerase chain reaction (PCR) of genomic DNA extracted from peripheral blood followed by fluorescence analysis of the size of the PCR fragments obtained by genetic analyzer and conversion of that size in the number of CTG repeats.
Patients who can benefit from this determination are those referred by a specialist. The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.
Log in to see the product files.
BDR
CE-IVD
Company